NeuroSense Therapeutics (NRSN) Accounts Payables (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Accounts Payables of $799000.0 for Q4 2025, down 26.9% sequentially from $1.1 million in Q2 2025, and down 31.12% YoY from $1.2 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Accounts Payables (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Accounts Payables for 6 years, with the latest figure at $799000.0 in Q4 2025.
- Quarterly Accounts Payables fell 31.12% year-over-year to $799000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $799000.0 (down 31.12% YoY) and the FY2025 annual result came in at $799000.0, down 31.12% from the prior year.
- Accounts Payables retreated to $799000.0 in Q4 2025 per NRSN's latest filing, from $1.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $1.1 billion in Q2 2023 and troughed at $65000.0 in Q4 2021.
- A 5-year average of $73.5 million and a median of $913000.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 908233.33% in 2023, then slumped 99.86% in 2024.
- Over 5 years, Accounts Payables stood at $65000.0 in 2021, then jumped by 666.15% to $498000.0 in 2022, then surged by 192.97% to $1.5 million in 2023, then dropped by 20.49% to $1.2 million in 2024, then sank by 31.12% to $799000.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $799000.0, $1.1 million, and $1.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 799,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 799,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 913,000.00 |
| Jun 30, 2023 | 1.09 Bn |
| Mar 31, 2023 | 419,000.00 |
| Dec 31, 2022 | 498,000.00 |
| Sep 30, 2022 | 206,000.00 |
| Jun 30, 2022 | 120,000.00 |
| Mar 31, 2022 | 180,000.00 |
| Dec 31, 2021 | 65,000.00 |
| Dec 31, 2020 | 55,000.00 |